Volanesorsen for treating familial chylomicronaemia syndrome
KEYWORDS: volanesorsen, committee, clinical, treatment, levels, patients, people, fcs, company, approach, model, risk, noted, erg, utility

the summary of product characteristics. 3.3 Before starting treatment with volanesorsen, platelet count should be measured. If it is below 140×109 per litre, another measurement should be taken about a week later to reassess. If platelet count remains below 140×109 per litre at a second measurement, treatment should not be started. Because of concerns about thrombocytopenia, an enhanced monitoring scheme has been implemented during clinical trials and in clinical practice. For full details of monitoring schedules, see the summary of product characteristics. 3.4 The price of volanesorsen for a single-use syringe (285 mg) is £11,394 (excluding VAT; company's evidence submission). The company has a commercial arrangement. This makes volanesorsen available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount. 4 Consideration of the evidence The evaluation committee (see section 6) considered evidence submitted by Akcea Therapeutics, the views of people with the condition, those who represent them and clinical experts, NHS England and a review by the evidence review group (ERG). See the committee papers for full details of the evidence. In forming the recommendations, the committee took into
